Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Next Previous
Search
Trial Profile

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telaglenastat (Primary) ; Cabozantinib; Docetaxel; Erlotinib; Everolimus; Paclitaxel
  • Indications Advanced breast cancer; Bone cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal stromal tumours; Liver cancer; Malignant-mesothelioma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors Calithera Biosciences

    • Most Recent Events

    • 09 Feb 2022 Results evaluating the telaglenastat plus cabozantinib or everolimus, agents known to impair glucose metabolism in patients with metastatic RCC, published in the Clinical Cancer Research.
    • 20 Jul 2021 Results (n=120) assessing the recommended phase 2 dose and evaluate safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity by exploratory tumor-/biomarker-specific cohorts, published in the Clinical Cancer Research.
    • 13 Feb 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top